Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05457270 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

A Phase 1 study of Healthy Volunteers, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT05457270 is a Phase 1 study of Healthy Volunteers that has completed, run by AstraZeneca. The registered enrollment target is 30 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05457270, a Phase 1 study of Healthy Volunteers, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

A study to assess the relative bioavailability and safety of different formulations of AZD4831 in fasted state in healthy volunteers.

Conditions Studied

Interventions

  • DRUG AZD4831

Study Locations (1)

Maryland

  • Research Site - Brooklyn

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-08-11
Est. Completion 2022-10-17
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT05457270

The ClinicalTrials.gov registry entry for NCT05457270 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (94% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which AZD4831 is the first listed.

NCT05457270 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT05457270 about?

NCT05457270 is a clinical study titled "A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.". A study to assess the relative bioavailability and safety of different formulations of AZD4831 in fasted state in healthy volunteers.

What is the current status of trial NCT05457270?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-08-11. Estimated completion is 2022-10-17.

What conditions does trial NCT05457270 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT05457270?

The interventions under investigation include: AZD4831 (DRUG).

Who is sponsoring clinical trial NCT05457270?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05457270 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.